Artificial Intelligence for Drug Discovery Landscape Overview

Q2 / 2018 Industry Analysis

Section III (Investor and M&A Guide, 70 pages in length)

Section III: Comparative Industry Analysis & Classification Framework (Investor and M&A Guide), 70 pages in length, a section specifically tuned to industry professionals such as investors, analysts, BioPharma/Tech executives and decision-makers, is available for purchase. This section is devoted to an in-depth comparative and quantitative analysis of the entire AI for Drug Discovery landscape, utilizing advanced infographics and tangible parameters both for (1) ranking various AI for Drug Discovery companies according to their levels of scientific validation, clinical development, R&D and industry-application diversification, and overall prospects for future growth and for (2) classifying AI for Drug Discovery companies according to their type and number of distinct industry applications, proportion of AI specialists, number of patents and publications, use of next-generation AI technologies (e.g. GANs vs ML), and whether they utilize AI as a core component of their R&D or as a complementary element to enhance their primary, non-AI focus and business model.

To Get Full Access to the

Section III, please Contact Us

5b61e26759281e0494de6679_to ai-p-500.png
5b6083268b62147dccf8719d_AI for Advanced
5b608326cec62a3fdbab8258_AI for Advanced
AI for Advanced R&D and Drug Discovery 2